There are valid points in the short report, but it may present a buying opportunity for long-term investors. Shares of Hims & Hers (HIMS 0.85%) fell on Thursday after a short report was published by a short-seller. This kind of report can often send stocks lower, but is it a reason to panic or a buying opportunity? In this video, Travis Hoium digs into the report's claims and why this is bullish for investors. *Stock prices used were end-of-day prices of June 27, 2024. The video was published on June 28, 20 ...

GLP-1 drugs for obesity and weight loss, which have shown to be extremely effective, are currently one of the most profitable and exciting trends in the market today. The market has been dominated by pharmaceutical giants Eli Lilly ((LLY) and Novo Nordisk ((NVO). However, I see significant opportunities for less mature companies like Hims & Hers Health to get involved. Hims & Hers Health (HIMS) already boasts a Zacks Rank #1 (Strong Buy) rating, reflecting the significant upward revisions to its earnings. H ...

Shares of online pharmacy Hims & Hers (HIMS -7.77%) dropped as much as 12.8% on Thursday after a shortseller wrote a report about the company. Shares recovered slightly during trading and are down 7.8% at 2:30 p.m. ET today. The short-seller's report In this case, Hunterbrook criticized Hims & Hers' GLP-1 weight-loss treatment, which is a compound made by a pharmacy and temporarily approved to fill shortages of GLP-1 drugs, and not a government-approved medication itself. There are questions, even by the Fo ...

Hims & Hers Health (NYSE:HIMS) stock is taking a tumble after Hunterbrook Media released a short report on the telehealth company. Hunterbrook operates an interesting business model, as it publishes research on stocks through Hunterbrook Media while sometimes taking a position in the same stock through its hedge fund affiliate, Hunterbrook Capital. In this instance, the hedge fund has disclosed that it is short HIMS stock. The premise of Hunterbrook's short report lies on Hims' compounded GLP-1 weight-loss ...

The company's stock has climbed by 31.22% in the past month, exceeding the Medical sector's gain of 0.61% and the S&P 500's gain of 2.73%. The investment community will be closely monitoring the performance of Hims & Hers Health, Inc. in its forthcoming earnings report. It is anticipated that the company will report an EPS of $0.05, marking a 266.67% rise compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $297.53 million, up 43.1 ...

12 Month EPS Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision. Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earn ...

Hims & Hers Health, Inc. (HIMS) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Over the past month, shares of this company have returned +67%, compared to the Zacks S&P 500 composite's +3.5% change. During this period, the Zacks Medical Info Systems industry, which Hims & Hers Health falls in, has lost 1.5%. The key question now is: What could be the stock's futu ...

Hims & Hers Health, Inc. (HIMS) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past month, shares of this company have returned +35%, compared to the Zacks S&P 500 composite's +4.8% change. During this period, the Zacks Medical Info Systems industry, which Hims & Hers Health falls in, has lost 8.2%. The key question now is: What could be the stock's future direction? While m ...

I challenge you to name another $20 stock with more long-term potential. Raging hot inflation has made it harder to find value in anything these days. A $20 bill doesn't go as far as it once did. But don't get discouraged; that money can go a long way if you know where to put it. Yes, even in the stock market, you can still get a lot for $20. Red-hot telehealth company Hims & Hers Health (HIMS 6.63%) recently exploded to nearly $20 per share on a major product announcement. Here's why this is arguably the b ...

GLP-1s could be the product that pushes Hims & Hers over the edge to mainstream adoption. Hims & Hers (HIMS -5.59%) has been a great growth stock since coming public, but it's now starting to turn a profit. In this video, Travis Hoium highlights the company's financials and why the launch of GLP-1 medications could be a game-changer. *Stock prices used were end-of-day prices of May 20, 2024. The video was published on May 21, 2024. ...